Sana Biotechnology

### Executive Summary Sana Biotechnology has raised $41.0M in a Regulation D private placement as of first sale date 2025-10-12, with related persons including Shield Capital and Founders Fund. The company operates in the synthetic biology & intracellular mRNA delivery sector, signaling strong investor demand in gene editing and mRNA therapeutics. ### Investor Edge Watch for any future Form D amendments (D/A) that disclose the total offering amount or new investors, as this initial raise may be a tranche of a larger round. Also monitor for subsequent press releases or patent filings mentioning 'intracellular mRNA delivery' to gauge technology maturation. ### Sector capital positioning This capital raise adds to the ongoing flow of private investment into synthetic biology and targeted mRNA delivery, areas that continue to attract top-tier venture backers despite a cautious broader market. ### Convergence Signals No direct public signals (patents, contracts, or legislation) are obvious from this filing alone; however, the involvement of Founders Fund and Shield Capital suggests a platform technology angle that may intersect with next-generation cell therapy or in vivo gene editing. ### Key Takeaways - Sana Biotechnology raised $41.0M in a private Reg D placement with backing from Shield Capital and Founders Fund. - The company focuses on synthetic biology and intracellular mRNA delivery, a high-growth sector. - No public ticker exists; this is a private placement, not a public offering. ### Risk Indicators & Flags No D/A amendments are present in this filing. However, the state is listed as 'Unknown,' which may indicate incomplete disclosure or a multi-state offering. The amount ($41M) is moderate for synthetic biology — not a red flag, but warrants monitoring for future amendments or regulatory inquiries. ### Verification & References This data comes from SEC Form D accession number 0001702600-24-20015, filed by Sana Biotechnology, a private company. First sale date is 2025-10-12. Related persons are listed as Shield Capital and Founders Fund. Verify at SEC EDGAR using the accession number.